Novel radiation mitigators and anticancer drugs Yel002 and CJ010

Robert H. Schiestl, RadMit Holding Inc. pls visit my website www.radmitinc.com and contact me at info@radmitinc.com for a private placement memorandum

RadMit Holding, Inc. focuses on the development of novel small molecule drugs to treat genomic instabilities and to mitigate diseases caused by accidental radiation exposure by boosting cellular DNA repair capabilities. The Company will primarily focus on development of treatments for genetic instability diseases such as Ataxia Telangiectasia (Lois-Barr Syndrome) as well as Xeroderma pigmentosa, Bloom’s Syndrome, Nijmegen Breakage Syndrome, Fanconia Anemia and Li Fraumeni Syndrome. In addition, the Company focuses on the development of a small molecule drug for the treatment of genomic instabilities caused by accidental exposure to radiation. There is strong commercial interest from pharmaceutical companies in new drugs for orphan diseases.

RadMit Holding Inc. (RadMit) has been founded by Prof. Robert H. Schiestl and the Management Team and incorporated in Los Angeles. The company primarily applies for non-dilutive US research funding (i.e. NIH SBIR grants, BARDA contracts) to support the Company’ research undertakings. RadMit intends to raise a total of $ 60 Million from venture capital investors in order to fund the preclinical and in part the clinical development of its two lead small molecule compounds for the treatment of Ataxia Telangiectasia and for mitigation of damages caused by radiation exposure.

The Company’s scientific founder has invented a proprietary screening assay against radiation induced genetic instability and toxicity at the University of California Los Angeles (UCLA). Using this proprietary assay, Prof. Schiestl and his team screened more than 16,000 small molecule compounds for efficacy to boost DNA repair proteins after radiation exposure. This substantial screening process resulted in the identification of several hits, the two most promising being Yel002 and CJ010. From mice irradiated with an LD100 which all die from the radiation, we could rescue 100% after injecting the first dose of our radiation mitigator 24 hours after radiation. Radiation induced leukemia was reduced from 90% down to 40%. Atm deficient mice of which 90% die from lymphoma lived 16 weeks longer after weekly injection with our radiation mitigator. This is equivalent to 12 years in human life expectancy which would cause AT patients to increase their life expectancy to 34 years from currently 22 years which is a more than a 50% increase. This would be a major advance in the management of the disease. In vitro proteomics experiments showed that our radiation mitigator induced DNA repair which is our own bodily defence against external and internal toxic substances. In particular it induced Atm signalling, nonhomologous end joining, base excision repair, DNA damage binding protein and structural maintenance of chromosome proteins. It also protected cells against chemical carcinogens, UV light, radioactive iodine, and cigarette smoke extract. Thus, uses include a novel biological sunscreen undoing the damage to the skin rather than shielding, and for smokers after smoking a cigarette do undue the smoking damage. It also prolonged the life of normal cells undergoing senescence which is ageing. Thus, our drugs could result in longer cancer free life making everyone a potential customer.

Based on these results, the Company believes that its lead substances are exceptionally well suited for the treatment of Ataxia Telangiectasia (AT) and other genetic instability and DNA repair deficient diseases with the aim to reduce the cancer risk in such patients and for the mitigation of damages caused by radiation exposure. It is a completely novel paradigm to use a chemical overexpressing DNA repair proteins for radiation mitigation and in cancer chemoprevention.

The Company has a worldwide exclusive license to 3 patent applications filed by the University of Los Angeles claiming the lead substances for the mitigation and treatment of symptoms of genomic instability disorders and as radiation mitigators. In addition, the Company plans to file further patent applications covering additional product candidates to achieve maximum IP protection for its products. With the many uses this drug could develop into a blockbuster drug.